What is Artiva Biotherapeutics, Inc.'s return on equity?

Artiva Biotherapeutics, Inc. (ARTV) reported return on equity of -67.9% in Q1 2026.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

Artiva Biotherapeutics, Inc. ARTV Return on equity

Return on equity at other companies

Bristol-Myers SquibbBMY

38.8%+7.3pp

Gilead SciencesGILD

43.2%+10.7pp

Kyverna Therapeutics, Inc.KYTX

-74.5%+74.4pp

Allogene TherapeuticsALLO

-52.3%-5.7pp

Immix Biopharma, Inc.IMMX

-74.4%-18.6pp

Cullinan Therapeutics, Inc.CGEM

-44%+26.2pp

Other financials

Income statement

See full

Revenue-—

Operating income-$24.4M-10.2%

Net income-$23.5M-15.8%

EPS (diluted)-$0.95-14.5%

Balance sheet

See full

Cash & equivalents$21.4M-30.6%

Total debt$10.3M-26.7%

Total equity$87.8M-48.0%

Total assets$106.0M-44.6%

Cash flow

See full

Operating cash flow-$21.0M-5.6%

CapEx$242.0K-52.6%

Free cash flow-$21.2M-4.1%

Valuation

See full

Market cap$429.03M+1,015%

Enterprise value$417.88M+1,832%

Profitability

See full

Operating margin-83.9%—

Net margin-79.3%—

Returns & leverage

See full

Debt / equity0.1×0.0×

Current ratio8.2×-5.8×

Where this comes from

Calculated from Artiva Biotherapeutics, Inc.’s reported figures.

net income/total stockholders equity=-67.9%

Based on trailing twelve months.

The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s return on equity?: Artiva Biotherapeutics, Inc. (ARTV) reported return on equity of -67.9% in Q1 2026.
What does return on equity mean?: Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.